BAGSVAERD, DENMARK--(Marketwired - May 17, 2013) - Novo Nordisk today announced the completion of paradigm™ 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm™ 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients with haemophilia B.
Company announcement No 37 / 2013: http://hugin.info/2013/R/1702902/562797.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1702902]
Further information Media: Mike Rulis +45 3079 3573 Email Contact Ken Inchausti (US) +1 609 514 8316 Email Contact Investors: Kasper Roseeuw Poulsen +45 4442 4303 Email Contact Frank Daniel Mersebach +45 4442 0604 Email Contact Lars Borup Jacobsen +45 3075 3479 Email Contact Jannick Lindegaard (US) +1 609 786 4575 Email Contact